+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and tolerability of HRS-7525 tablets in males with advanced prostate cancer. This Phase I clinical trial aims to identify the dose limiting toxicity, the maximum tolerated dose if possible, and the recommended Phase II dose of HRS-7525. The study focuses on patients with metastatic prostate adenocarcinoma who have a life expectancy of at least 12 weeks and good performance status. Participants will receive HRS-7525 tablets in a single-group study design. The trial includes a single-dose run-in period lasting 2 days followed by 21 days after the first administration to assess dose limiting toxicity. Safety follow-up will continue for about 13 months to evaluate the maximum tolerated dose and the recommended dose for further studies. Throughout the study, participants will be closely monitored with assessments related to safety and tolerability. Researchers will observe adverse events and collect data from the time of informed consent through the safety follow-up period. The total participant involvement may last up to approximately 13 months, during which the safety and pharmacokinetics of HRS-7525 will be evaluated.

Age: 18Years - 80YearsMALEPhase 1
7 locations
P

Actively Recruiting

Researchers are conducting a Phase 12a clinical trial to evaluate the safety and tolerability of DB-1311BNT324 in adults with advanced solid tumors that have progressed after standard treatments or have no available standard options. The trial aims to find the maximum tolerated dose and recommended dose for further study, as well as explore preliminary antitumor activity in selected cancers including prostate cancer. The study is multicenter, open-label, and includes a drug-drug interaction sub-study to assess the effects of other medications on DB-1311. In Phase 1, participants receive escalating single doses of DB-1311BNT324 every three weeks to determine safety and optimal dosing. Phase 2a expands dosing to confirm safety and explore effectiveness of DB-1311 given alone or combined with hormone therapies such as enzalutamide or abiraterone in prostate cancer. Treatment cycles are repeated every 21 days via intravenous infusion. Some participants receive additional oral medications to study interactions. The trial includes various cohorts with different tumor types and prior treatment histories. Participants undergo multiple assessments including safety labs, vital signs, ECGs, heart function tests, and performance status evaluations throughout treatment and for about one year after. Tumor response is measured using standard criteria, along with pharmacokinetic and immunogenicity tests. Researchers monitor adverse events and serious events continuously. The total participation lasts up to approximately one year post-treatment to evaluate safety, dosing, and preliminary outcomes.

Age: 18Years +All GendersPhase 1Phase 2
107 locations
F

Actively Recruiting

Researchers are evaluating CT-202, a new humanized T cell engaging bispecific antibody targeting nectin-4, in people with nectin-4 positive recurrent, unresectable, or metastatic triple negative breast cancer TNBC, colorectal cancer CRC, or urothelial cancer UC that are resistant to standard treatments. This Phase 1a1b trial aims to assess the safety, tolerability, and early signs of effectiveness of CT-202. Results from this study including pharmacokinetics, pharmacodynamics, efficacy, and safety will help determine the recommended dose for future studies. The study includes two parts Phase 1a dose escalation uses a Bayesian Optimal Interval design with step-up dosing every two weeks across approximately six dose levels. Participants will continue treatment until disease progression, unacceptable side effects, withdrawal, or investigator decision. Phase 1b dose expansion will test CT-202 at two or more doses and dosing schedules across 4 to 6 groups of up to 15 participants each, focusing on the same cancer types. Data from Phase 1b will guide the recommended Phase 2 dose. Participants will undergo regular evaluations including safety monitoring and tumor assessments up to 24 months after the first dose. The main outcomes measured are dose limiting toxicities during Phase 1a and overall response rate during Phase 1b. The study includes participants aged 18 and older with measurable disease and adequate organ function. The treatment is given intravenously every two weeks, and participants are observed until disease progression or other study endpoints.

Age: 18Years +All GendersPhase 1
6 locations
F

Actively Recruiting

Researchers are conducting the FLUDRO-SHOCK trial to find better treatments for adults with septic shock, a serious condition caused by severe infection. This phase 3 international trial compares two doses of the steroid fludrocortisone 50 mcg and 100 mcg against a placebo, alongside the usual hydrocortisone treatment. The study also investigates how a persons gene-based immune response may influence treatment effects. Up to 2,200 critically ill patients in intensive care units across multiple countries are expected to participate. Participants will receive either 50 mcg or 100 mcg of fludrocortisone acetate daily, or a matching placebo tablet, given orally or through a gastric tube for 7 days or until discharge from intensive care, whichever comes first. The study uses a randomized, double-blind design to fairly compare these treatments. Researchers will closely monitor patients during this treatment period. Throughout the study, participants survival, organ support needs, and quality of life will be tracked for up to one year after enrollment. Assessments include the number of days alive without organ support, mortality at multiple time points, new kidney therapy needs, mechanical ventilation days, hospital readmissions, new infections, and functional and health-related quality of life questionnaires. This comprehensive monitoring aims to help identify the most effective and personalized steroid treatment approach for septic shock.

Age: 18Years +All GendersPhase 3
8 locations
T

Actively Recruiting

This research aims to evaluate treatments for patients who arrive at the emergency department with acute ischemic stroke caused by basilar artery occlusion within 24 hours of symptom onset. The study compares the use of tenecteplase, a clot-busting drug, against standard care which may include alteplase or no thrombolytic treatment, with the goal of improving functional outcomes at 90 days after stroke. It is a multi-arm, multi-stage, randomized trial designed to adaptively assess treatment effects and proceed seamlessly from phase 2b to phase 3 based on early results. Participants are randomly assigned to one of two groups one receiving intravenous tenecteplase at a dose of 0.25 mgkg given as a quick bolus, and the other receiving standard care that may include intravenous alteplase at 0.9 mgkg or no thrombolytic treatment. Both groups may undergo mechanical thrombectomy if deemed necessary by their treating doctors. The study uses a computer-based randomization process and will monitor patients through an adaptive sample size plan, with a minimum of 320 and up to 688 patients over about five years. During the trial, participants will be followed for 12 months. Researchers will assess stroke recovery using the modified Rankin Scale at 90 days as the primary outcome, along with other measures like quality of life, early clinical improvement, and safety outcomes such as bleeding in the brain. Assessments include angiography, brain imaging, and clinical evaluations at multiple time points. This ongoing monitoring will help determine which treatment offers better functional recovery and safety for stroke patients with basilar artery occlusion.

Age: 18Years +All GendersPhase 2Phase 3
17 locations
F

Actively Recruiting

Mycobacterium abscessus MABS is a group of rapidly growing bacteria resistant to many drugs, causing lung infections that can lead to serious health problems, decreased lung function, and higher risk during lung transplants. The prevalence of MABS infections is increasing globally despite the relatively small number of affected people. The Finding the Optimal Regimen for Mycobacterium abscessus Treatment FORMaT trial aims to identify the best treatment combinations to improve health outcomes while reducing side effects and treatment burden. It also seeks to develop biomarkers to guide treatment decisions and assess disease severity in patients with MABS pulmonary disease MABS-PD. The trial is an ongoing, adaptive study designed to test and improve combinations of therapies for both children and adults with MABS-PD. Participants receive various drug treatments including intravenous therapies such as amikacin, tigecycline, cefoxitin or imipenem combined with oral antibiotics like azithromycin, clarithromycin, and clofazimine. The study includes phases of intensive intravenous therapy followed by consolidation therapy with oral andor inhaled antibiotics. Treatments can be adjusted based on tolerance and microbiological response, with new therapies added or removed as evidence evolves. Participants are involved in screening, treatment, and follow-up visits extending up to 62 weeks. The study monitors microbiological clearance of infection alongside treatment tolerance. Assessments include lung function tests, chest CT scans, quality of life questionnaires, six-minute walk tests, and evaluation of treatment safety and resistance. Researchers also study health costs and reasons for early withdrawal. This comprehensive monitoring helps understand how treatments affect disease control, lung health, and patient well-being over time.

All AgesAll GendersPhase 2Phase 3
50 locations
R

Actively Recruiting

This research aims to evaluate whether early use of enteral fludrocortisone can reduce death and dependency six months after aneurysmal subarachnoid haemorrhage aSAH, a severe type of stroke that mainly affects adults aged 45 to 64 and more often women. The condition has a high mortality rate and many survivors face lasting neurological and cognitive problems, impacting their quality of life and ability to work. The study will address the need for better treatment options given the high healthcare costs and poor outcomes associated with aSAH. Participants will be randomly assigned to receive either fludrocortisone or a matched placebo tablet every six hours by mouth for 14 days. Fludrocortisone is a synthetic steroid that helps retain sodium and fluids, potentially preventing hyponatraemia, a common and serious complication of aSAH that can worsen brain swelling and increase the risk of further brain injury. This trial is blinded and controlled to compare the effects of fludrocortisone against placebo in critically ill patients. During the study, participants will be monitored in a critical care setting with regular assessments including neurological evaluations and laboratory tests. The main outcome measured will be the level of disability or recovery at six months using the Modified Rankin Scale. Additional assessments will include quality of life tools specific to subarachnoid haemorrhage. Safety and side effects will be closely observed throughout the study. The total duration of participation includes treatment and follow-up assessments up to six months after randomization.

Age: 18Years +All GendersPhase 2
16 locations
P

Actively Recruiting

Researchers are studying patients with stage II primary invasive cutaneous melanoma to compare the effects of two different surgical excision margins 1cm versus 2cm. The goal is to determine if narrower margins are as safe as wider margins in preventing melanoma recurrence and if they can improve patients quality of life. This trial also looks at the impact of these excision sizes on health services and society. Participants will be randomly assigned to receive either a 1cm or 2cm wide local excision margin around the primary melanoma lesion. Both groups will undergo sentinel lymph node biopsy and may have reconstruction surgery if needed. The surgery must be done within 120 days of diagnosis and within 28 days of randomization. During the study, participants will be followed for up to 60 months to measure disease-free survival as the primary outcome. Additional assessments include local recurrence, distant disease-free survival, melanoma-specific and overall survival, quality of life questionnaires, neuropathic pain evaluations, adverse event monitoring, and health economic analysis. Follow-up questionnaires and safety checks will occur at multiple time points up to 24 months after surgery, with longer-term monitoring continuing up to 120 months.

Age: 18Years +All GendersPhase Not Applicable
192 locations
I

Actively Recruiting

Healthy Volunteer

Researchers are evaluating different ways to increase the use of antimicrobial stewardship AMS resources by doctors treating adults with respiratory tract infections in Australian general practices. The study compares two methods of delivering AMS education and support face-to-face activities Integrated Network versus virtual or online activities Virtual Network. The goal is to see which approach leads to more frequent use of AMS interventions to guide antibiotic prescribing. Doctors in the trial receive about 7 hours of AMS education and support through either online self-paced modules, guided self-audits, and podcasts Virtual Network, or live interactive webinars, peer-group audits, and online forums Integrated Network. Participating doctors use an online AMS Toolbox when treating patients to record intervention use and antibiotic prescribing. A subgroup of doctors and patients also take part in interviews and use point-of-care tests to help identify the cause of infections. Participants provide data through online surveys, where doctors log their AMS intervention use and patient numbers, and patients report their experience of care. Interviews with selected doctors, staff, and patients explore their views on the interventions. The primary outcome is the change in AMS intervention use per 100 consultations over two 5-month winter periods, before and after the implementation activities. The study runs from baseline data collection, through the implementation phase, and into post-intervention follow-up.

Age: 18Years +All GendersPhase Not Applicable
4 locations
T

Actively Recruiting

Researchers are evaluating the use of intra-arterial tenecteplase given at the end of mechanical thrombectomy in adults with acute ischemic stroke caused by a blockage in a large artery in the brain. This randomized, placebo-controlled trial compares tenecteplase to standard care with a saline placebo to study its safety and effectiveness within 24 hours of stroke symptom onset. The study is a phase 2b3 trial designed to test early neurological improvement and longer-term functional independence in participants. Participants receive either an intra-arterial bolus of tenecteplase dosed by weight maximum 6.25 mg or a placebo saline bolus administered directly at the site of the original artery blockage after thrombectomy. The trial includes two groups with equal chance of assignment and uses a double-blind design. The intervention occurs immediately after thrombectomy, targeting residual clots that may cause ongoing blood flow issues. During the study, participants are monitored for neurological improvement within 24 to 36 hours and functional independence at three months. Additional assessments include brain imaging to measure infarct growth and no-reflow, safety monitoring for bleeding events, mortality rates, and quality of life evaluation. The trial lasts at least three months from randomization, with multiple visits and tests to track outcomes and side effects.

Age: 18Years +All GendersPhase 2Phase 3
12 locations

1-10 of 15

1